Pneumonia, Ventilator-associated Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects
The purpose of this study is the prevention of Staphylococcus aureus pneumonia in mechanically ventilated subjects heavily colonized with S. aureus. Staphylococcus aureus is a human pathogenic bacterium that causes severe infections, including pneumonia and sepsis. Hospital-acquired bacterial pneumonia (HABP) caused by S. aureus, including ventilator-associated bacterial pneumonia (VABP) in mechanically ventilated subjects, is a significant public health threat despite efforts to optimize antibiotic treatment. ASN100 is an investigational monoclonal antibody product that targets the toxins produced by S. aureus to protect subjects from developing S. aureus pneumonia.
This is a double-blind, randomized, single-dose, placebo-controlled study of ASN100 for the
prevention of S. aureus pneumonia in mechanically ventilated subjects who are heavily
colonized with S. aureus. This will be a global study conducted at approximately 65 sites to
assess the safety, tolerability, and efficacy of ASN100.
Eligible subjects who meet all of the inclusion criteria and none of the exclusion criteria
will be screened by semi-quantitative culture of an endotracheal aspirate (ETA) to identify
those who are heavily colonized with S. aureus (3+ to 4+). Upon determination of eligibility,
subjects will be randomized in a 1:1 ratio to 1 of 2 treatment groups, ASN100 or placebo.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06370598 -
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
|
Phase 1/Phase 2 | |
Terminated |
NCT02806141 -
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
|
Phase 3 | |
Completed |
NCT01765530 -
Efficacy Study of a Novel Device to Clean the Endotracheal Tube
|
N/A | |
Completed |
NCT00521677 -
Comparison Between Two Methods of Oral Care on the Incidence of VAP
|
N/A | |
Completed |
NCT00529776 -
Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy
|
N/A | |
Completed |
NCT03401463 -
Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar
|
N/A | |
Completed |
NCT02950519 -
Endotracheal Tube Cuff Pressures in Ventilated Patients
|
N/A | |
Completed |
NCT01875692 -
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
|
N/A | |
Completed |
NCT00515034 -
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
|
Phase 2 | |
Recruiting |
NCT05117125 -
Biomarkers for Ventilator-associated Pneumonia
|
||
Completed |
NCT04755972 -
Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2
|
N/A | |
Completed |
NCT01577862 -
Colistin and Rifampicin for MDR-Acinetobacter
|
Phase 3 | |
Completed |
NCT00572559 -
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
|
Phase 4 | |
Withdrawn |
NCT04566172 -
Preoperative Optimization to Improve Functional Status
|
N/A | |
Recruiting |
NCT04215692 -
Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients
|
N/A | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Active, not recruiting |
NCT01123681 -
Intubation and Extubation Over 48 Hours Mechanical Ventilation
|
N/A | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03527992 -
Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia
|
N/A | |
Recruiting |
NCT05405491 -
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
|
N/A |